Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Phot... ( LINCOLN R.I. May 28 /- Neurotech Phar...)

HOME >> BIOLOGY >> TECHNOLOGY

Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors

Date:5/28/2009

LINCOLN, R.I., May 28 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc. today announced that the Company's product candidate, NT-501, demonstrated a strong biologic effect in two Phase 2 clinical trials for retinitis pigmentosa (RP). RP is a slowly developing condition that causes the progressive degeneration of rod & cone photoreceptor cells in the retina that over time diminishes night and peripheral vision and eventually leads to blindness. RP is an orphan-designated indication for which there are currently no approved treatments.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090528/NE23594LOGO )

In both studies, there was a statistically significant (p< 0.001 for the high dose group in each study), dose-dependent increase in retinal thickness involving photoreceptor layers as measured by optical coherence tomography (OCT). This statistically-significant effect has also been observed in a recently completed Phase 2 NT-501 study in patients with geographic atrophy associated with dry age-related macular degeneration (AMD), the results of which were reported by Neurotech on March 26, 2009. This effect, which is believed by the Company to be neuroprotective, has also been demonstrated in animals.

NT-501 is an intraocular implant that consists of human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). CNTF, a growth factor capable of rescuing and protecting dying photoreceptors, is delivered directly to the back of the eye in a controlled, continuous basis by means of the Company's proprietary Encapsulated Cell Technology (ECT) platform. Delivery via ECT bypasses the blood-retinal barrier and overcomes a major obstacle in the treatment of retinal disease.

T
'/>"/>

SOURCE Neurotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results
2. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
3. Martek to Announce Second Quarter 2009 Results
4. Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
5. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
6. Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business
7. Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
8. China Biologic Products Announces Strong First Quarter 2009 Results
9. China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results
10. China Biologic Products Announces 2009 First Quarter Results Conference Call
11. PharmAthene Reports First Quarter 2009 Financial and Operational Results

Post Your Comments:

(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7

(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s

(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of

(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1

Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2 Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2 Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3 The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2 The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3 Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2 Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3

[0] Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results [0] Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators [0] The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference [0] Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies

...ANTIPOLIS, France, February 26 NicOx,S.A. (NYSE E...results for,full year 2008 and provided an overvie...ivities for naproxcinod, its lead investigational,...f osteoarthritis (OA). , Michele Garufi, Chief...e,NicOx has entered 2009 in its strongest strategi...

...o understand friction on a very small scale, a tea... to think big. , Friction is a force that affect...tact; the more surface contact there is, the stron...f a meter friction can wreak havoc on tiny device...les. With their high surface-to-volume ratio, nano...

... Feb. 25 Cornerstone Therapeutics Inc. (Nasdaq: ...d on developing and commercializing prescription m...ced that it will host a conference call at 8:30 AM...nancial results for the quarter and year ended Dec...pdate on the Company,s strategy, operations and pr...

Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value Models present new view of nanoscale friction Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call

(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today

(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O

(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne

[0] Forest deal at Copenhagen must avoid creating 'carbon refugees'[0] CCNY professor foresees rising Antarctic snowmelt [0] Head and neck cancer survivors who use alcohol and cigarettes have increased death risk

...ading life scientists from Europe and around the w...ar Biology Organization (EMBO) for their proven ex..., distinguished as EMBO Members, are from Europe a...pected scientists come from other parts of the wor...rent membership total to 1360. , Membership is a ...

... Research , a journal of the American Association ...nicotine in breast tumor development and metastase...Beth Israel Deaconess Medical Center, is among the...ry cells. , "Although numerous studies indicate ...little is known about the effect of nicotine on br...

...other planets and in extreme environments on Earth...y initiative under a five-year grant from NASA,s A... Earth and Beyond." , Christopher H. House, assoc...isciplinary team to develop methods to detect and ...in relevant ecosystems in ancient rocks and other ...

Other Biology News:EMBO honors 59 leading life scientists 2 Study links nicotine with breast cancer growth and spread 2 Penn State receives new NASA astrobiology grant 2 Penn State receives new NASA astrobiology grant 3

EMBO honors 59 leading life scientists Study links nicotine with breast cancer growth and spread Penn State receives new NASA astrobiology grant

Criterion Staining and Blotting Trays, with lids, 12 from Bio-Rad

...orating a wide range of next-generation features i... standard for flexible laboratory solutions. It pu...tting, dilution, dispensing, and integrations int... flexible as it is efficient and economical. The B...

...ek FX P is the latest entry in the Biomek line. W... positional accuracy and increased robustness, it ...It can be configured with either one or two pipett... FX P sets the standard for flexible laboratory s...

BD Falcon 96-well Flat-bottom ELISA Plates from BD Biosciences - Discovery Labware

Biology Products:

Criterion Staining and Blotting Trays, with lids, 12 from Bio-Rad Biomek NX P Span-8 Laboratory Automation Workstation (w/ Gripper) from Beckman Coulter Biomek FXP Laboratory Automation Workstation with Single Span-8 Pod from Beckman Coulter BD Falcon 96-well Flat-bottom ELISA Plates from BD Biosciences - Discovery Labware

Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Phot...( LINCOLN R.I. May 28 /- Neurotech Phar...)